 diabet retinopathi non-insulin-depend diabet mellitu patient role gliclazid diabet retinopathi common caus human blind age industri world retinopathi multifactori etiolog standard treatment glucos metabol partial amelior certain hemobiolog factor addit metabol action gliclazid specif hemobiolog properti studi gliclazid anim human signific improv platelet abnorm stimul prostaglandin synthesi enhanc fibrinolyt activ human open-label studi gliclazid treatment stabil background retinopathi non-insulin-depend diabet benefici effect control studi month sulfonylurea japanes diabet retinopathi program progress retinopathi period gliclazid sulfonylurea placebo studi equival metabol control trend rate deterior incid preprolif retinopathi group sulfonylurea overal specif hemobiolog action gliclazid progress diabet retinopathi advantag incid preprolif retinopathi